State Street’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-1,650,696
| Closed | -$18.5M | – | 3793 |
|
|
2017
Q3 | $18.5M | Buy |
1,650,696
+142,643
| +9% | +$1.57M | ﹤0.01% | 2080 |
|
|
2017
Q2 | $16.6M | Sell |
1,508,053
-65,212
| -4% | -$652K | ﹤0.01% | 2120 |
|
|
2017
Q1 | $15.4M | Buy |
1,573,265
+139,877
| +10% | +$1.4M | ﹤0.01% | 2131 |
|
|
2016
Q4 | $15.5M | Sell |
1,433,388
-20,722
| -1% | -$207K | ﹤0.01% | 2074 |
|
|
2016
Q3 | $14.9M | Buy |
1,454,110
+200,511
| +16% | +$2.18M | ﹤0.01% | 1959 |
|
|
2016
Q2 | $16.4M | Buy |
1,253,599
+266,215
| +27% | +$3.49M | ﹤0.01% | 1898 |
|
|
2016
Q1 | $10.9M | Sell |
987,384
-87,713
| -8% | -$780K | ﹤0.01% | 2121 |
|
|
2015
Q4 | $9.89M | Sell |
1,075,097
-931,772
| -46% | -$7.8M | ﹤0.01% | 2189 |
|
|
2015
Q3 | $13.9M | Buy |
2,006,869
+158,832
| +9% | +$1.36M | ﹤0.01% | 1985 |
|
|
2015
Q2 | $18.1M | Buy |
1,848,037
+921,152
| +99% | +$8.39M | ﹤0.01% | 1922 |
|
|
2015
Q1 | $8.21M | Buy |
926,885
+17,277
| +2% | +$138K | ﹤0.01% | 2316 |
|
|
2014
Q4 | $7.97M | Sell |
909,608
-106,610
| -10% | -$863K | ﹤0.01% | 2329 |
|
|
2014
Q3 | $7M | Buy |
1,016,218
+40,443
| +4% | +$242K | ﹤0.01% | 2366 |
|
|
2014
Q2 | $5.14M | Sell |
975,775
-17,822
| -2% | -$86.7K | ﹤0.01% | 2581 |
|
|
2014
Q1 | $4.52M | Sell |
993,597
-127
| -0% | -$613 | ﹤0.01% | 2625 |
|
|
2013
Q4 | $5.01M | Sell |
993,724
-32,640
| -3% | -$157K | ﹤0.01% | 2577 |
|
|
2013
Q3 | $5.21M | Sell |
1,026,364
-9,774
| -0.9% | -$54.4K | ﹤0.01% | 2509 |
|
|
2013
Q2 | $5.14M | Buy |
+1,036,138
| New | +$4.93M | ﹤0.01% | 2454 |
|
State Street's SCLN Position: Q4 2017 in Review
State Street sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 1,650,696 shares — an estimated $18.5M sold.
State Street first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $18.5M in Q3 2017. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- State Street reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- State Street sold 1,650,696 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $18.5M.
- State Street first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- State Street's Sciclone Pharmaceuticals Inc position peaked at $18.5M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on State Street's 13F filing for Q4 2017, filed 14 Feb 2018.